Efficacy of combination therapy with Pembrolizumab and Bevacizumab in the treatment of platinum-resistant recurrent advanced ovarian cancer patients
Objective To observe the effect of Pembrolizumab combined with Bevacizumab in the treatment of plat-inum-resistant recurrent advanced ovarian cancer.Methods A total of 76 patients with advanced ovarian cancer treated in Jiujiang NO.1 People's Hospital from December 2018 to December 2022 were selected as the study objects,and they were divided into experimental group(38 cases)and control group(38 cases)according to computer randomization method.The control group was treated with Bevacizumab regimen,and the experimental group was treated with Pembrolizumab on the basis of the control group.The clinical efficacy,incidence of side effects,level of tumor markers and quality of life were compared between the two groups.Results There were no significant differences in the level of tumor markers between the two groups at the 2nd cycle of treatment(P＞0.05).The level of tumor markers in two groups at the 6th cycle of treatment were lower than those at the 2nd cycle,and the differences were statistically significant(P＜0.05).The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),carbohydrate antigen 153(CA153)and carbohydrate antigen 125(CA125)in experimental group were lower than those in control group at the 6th cycle of treatment,and the differences were statistically significant(P＜0.05).The objective response rate(ORR)and disease control rate(DCR)of experimental group were higher than those of control group,and the differences were statistically significant(P＜0.05).The total incidence of toxic and side effects in experimental group was lower than that in control group,and the difference was statistically significant(P＜0.05).The overall survival and progression-free survival of experimental group were longer than those of control group,and the differences were statistically significant(P＜0.05).Conclusion Pembrolizumab combined with Beva-cizumab is effective in the treatment of platinum-resistant recurrent advanced ovarian cancer,which can effectively improve the quality of life and prognosis of patients,reduce the expression level of tumor markers and the risk of toxic and side ef-fects,and has higher clinical efficacy and safety.
PembrolizumabBevacizumabPlatinum-resistant recurrent advanced ovarian cancerAdvanced ovarian cancer
万方数据
维普
